Feeds

Friends and families deal with drug trial fallout

Victims 'screamed'

Top 5 reasons to deploy VMware with Tegile

Details continue to emerge of the London drug test that put six volunteers in a critical condition.

Speaking to the Mirror, Dolores Flanagan, aunt of 21-year-old Ryan Wilson, one of the men that reacted badly to the drug, said: "The family are in pieces. He's in the hands of God now."

The Sun got hold of one of the more fortunate participants in the trial, who seems to have been given a placebo. Raste Khan said: "Some screamed out that their heads felt like they were going to explode."

Late this afternoon, authorities at Northwick Park Hospital in London said the condition of four of the men is showing signs of improvement. A statement said: "The other two men remain critical and it could be a while until they show significant change."

Student David O'Donnell, 19, was due to take part in the next stage of testing of the drug in April at a higher dose. A friend of his took part in the trial and is seriously ill. O'Donnel told the BBC: "I am very worried about him indeed, but I had a message from my friends to say they have managed to get in contact with him."

The distressed girlfriend of one of the men said yesterday that he looked like "the Elephant Man". Northwick Park intensive care clinical director Ganesh Suntharalingam tried to calm fears: "These patients sometimes need a lot of fluid, and one result of that is severe but temporary swelling. This is distressing for relatives to see, but it does go away on recovery and it has no long-term effects."

The experimental drug TGN1412 administered to the six was aimed at combatting immunological diseases - chronic conditions like rheumatoid arthritis, multiple sclerosis and leukaemia. German firm Tegenero had contracted American firm Parexel to carry out the first human trials for the new therapy in Britain.

TGN1412 is designed to target rogue T-cells which cause these illnesses. In the trial it triggered a massive inflammatory response in the healthy human volunteers, despite passing animal testing without problems.

TeGenero says it has apologised to the sick men's families.

A TeGenero statement says: "The drug was developed in accordance with all regulatory and clinical guidelines and standards."

Parexel works as a contractor running testing of many new drugs. It agreed that all guidelines had been followed. Its testing programmes draw in cash-strapped students with offers of easy money. Parexel's website trumpets: "Paid time to yourself."

It's unclear if there will be any kind of compensation pay out.

In an open letter to the British Medical Journal back in February, University of London Professor Desmond Laurence criticised the unclear arrangements for compensation when drug trials go wrong.

He said documents covering drug trials were not written in plain language and therefore did not meet the legal requirement of fairness and openness under consumer law. He observed: "The cost of compensation for non-negligent harm falls upon the injured patients themselves."®

Secure remote control for conventional and virtual desktops

More from The Register

next story
MEN: For pity's sake SLEEP with LOTS of WOMEN - and avoid Prostate Cancer
And, um, don't sleep with other men. If that's what worries you
Voyager 1 now EIGHTEEN LIGHT HOURS from home
Almost 20 BEEELION kilometres from Sol
HUGE SHARK as big as a WWII SUBMARINE died out, allowing whales to exist
Who'd win a fight: Megalodon or a German battleship?
Jim Beam me up, Scotty! WHISKY from SPAAACE returns to Earth
They're insured for $1m, before you thirsty folks make plans
ROGUE SAIL BOAT blocks SPACE STATION PODULE blastoff
Er, we think our ISS launch beats your fishing expedition
Comet Siding Spring revealed as flying molehill
Hiding from this space pimple isn't going to do humanity's reputation any good
BAE points electromagnetic projectile at US Army
Railguns for 'Future fighting vehicle'
OK Google, do I have CANCER?
Company talks up pill that would spot developing tumors
prev story

Whitepapers

Why cloud backup?
Combining the latest advancements in disk-based backup with secure, integrated, cloud technologies offer organizations fast and assured recovery of their critical enterprise data.
A strategic approach to identity relationship management
ForgeRock commissioned Forrester to evaluate companies’ IAM practices and requirements when it comes to customer-facing scenarios versus employee-facing ones.
Reg Reader Research: SaaS based Email and Office Productivity Tools
Read this Reg reader report which provides advice and guidance for SMBs towards the use of SaaS based email and Office productivity tools.
Storage capacity and performance optimization at Mizuno USA
Mizuno USA turn to Tegile storage technology to solve both their SAN and backup issues.
The hidden costs of self-signed SSL certificates
Exploring the true TCO for self-signed SSL certificates, including a side-by-side comparison of a self-signed architecture versus working with a third-party SSL vendor.